Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS)
Status:
Withdrawn
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
Acute Lung Injury/Acute respiratory distress syndrome (ALI/ARDS) is a serious and frequently
encountered entity in modern ICUs. Sepsis remains the most common cause of ALI/ARDS and
carries the worst prognosis. The disease is characterized by an intense inflammatory process.
This inflammation plays a major role in the development of gas exchange abnormalities seen in
the course of the disease. Statins, primarily used as lipid-lowering agents, are now known to
possess anti-inflammatory, antioxidant, antithrombogenic and vascular function-restoring
actions. Therefore the investigators propose to determine if Simvastatin may be useful in
decreasing the incidence of this deadly syndrome in critically ill patients.
Phase:
N/A
Details
Lead Sponsor:
University of Oklahoma
Collaborators:
US Department of Veterans Affairs VA Office of Research and Development